Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers

Abstract

Summary: PARP inhibitors have been shown to radiosensitize tumor cells in both in vitro and in vivo studies. This is a phase I study that aims to determine the safety, tolerability, and maximally tolerated dose of talazoparib, a PARP inhibitor, when delivered concurrently with radiotherapy in women with recurrent gynecologic cancers. Keywords: Talazoparib, Gynecologic cancer, Poly (ADP-ribose) polymerase, Radiotherapy, Dose escalation, Radiosensitizer, PARP-inhibitors